chlorpromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	621	50-53-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: chlorpromazine 2-Chloropromazine chlordelazin chlorderazin thorazine contomin chlorpromazine hydrochloride chlorpromazine HCl	The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Molecular weight: 318.86 Formula: C17H19ClN2S CLOGP: 5.50 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.88 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

chlorpromazine
2-Chloropromazine
chlordelazin
chlorderazin
thorazine
contomin
chlorpromazine hydrochloride
chlorpromazine HCl

The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.

Molecular weight: 318.86
Formula: C17H19ClN2S
CLOGP: 5.50
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 6.48
ALOGS: -4.88
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.10	g	P
0.30	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	400 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	52.37 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	11 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 18, 1957	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	223.99	21.43	78	7504	11052	50586490
Sopor	173.52	21.43	76	7506	19803	50577739
Drug abuse	170.39	21.43	108	7474	59738	50537804
Toxicity to various agents	152.99	21.43	173	7409	212326	50385216
Electrocardiogram QT prolonged	138.64	21.43	90	7492	51796	50545746
Catatonia	131.43	21.43	40	7542	3696	50593846
Overdose	109.37	21.43	102	7480	99625	50497917
Suicide attempt	103.28	21.43	75	7507	51657	50545885
Aggression	91.32	21.43	50	7532	21066	50576476
Intentional self-injury	89.79	21.43	51	7531	23061	50574481
Coma	81.98	21.43	68	7514	56811	50540731
Agitation	81.51	21.43	66	7516	53318	50544224
Mania	73.93	21.43	35	7547	10881	50586661
Psychotic disorder	68.61	21.43	42	7540	21770	50575772
Mental disorder	58.29	21.43	38	7544	21953	50575589
Intentional overdose	55.46	21.43	57	7525	62447	50535095
Tardive dyskinesia	51.32	21.43	24	7558	7255	50590287
Delusion	51.20	21.43	27	7555	10542	50587000
Hallucination, auditory	50.82	21.43	27	7555	10701	50586841
Depressed level of consciousness	49.04	21.43	49	7533	51904	50545638
Psychomotor hyperactivity	48.61	21.43	25	7557	9276	50588266
Cardiac arrest	48.22	21.43	61	7521	83590	50513952
Drug interaction	47.33	21.43	97	7485	199524	50398018
Completed suicide	46.35	21.43	76	7506	131813	50465729
Pneumonia aspiration	44.49	21.43	37	7545	30967	50566575
Sedation	42.83	21.43	36	7546	30574	50566968
Stereotypy	41.70	21.43	10	7572	372	50597170
Torsade de pointes	40.33	21.43	24	7558	11811	50585731
Somnolence	39.93	21.43	78	7504	154907	50442635
Hepatocellular injury	39.39	21.43	32	7550	25915	50571627
Grandiosity	39.14	21.43	9	7573	278	50597264
Arthralgia	39.05	21.43	9	7573	438693	50158849
Miosis	38.98	21.43	19	7563	6291	50591251
Salivary hypersecretion	38.19	21.43	19	7563	6572	50590970
Behaviour disorder	37.75	21.43	14	7568	2366	50595176
Poisoning deliberate	37.72	21.43	20	7562	7892	50589650
Tachycardia	37.08	21.43	59	7523	99704	50497838
Eosinophilic myocarditis	36.99	21.43	9	7573	356	50597186
Disorganised speech	36.51	21.43	11	7571	980	50596562
Hypotonia neonatal	36.45	21.43	11	7571	986	50596556
Pain	34.83	21.43	22	7560	578881	50018661
Epileptic encephalopathy	34.17	21.43	8	7574	268	50597274
Premature delivery	33.45	21.43	28	7554	23635	50573907
Mutism	32.92	21.43	11	7571	1370	50596172
Lactate pyruvate ratio increased	30.22	21.43	6	7576	90	50597452
Pain in extremity	30.14	21.43	3	7579	272862	50324680
Gaze palsy	29.34	21.43	10	7572	1323	50596219
Fatigue	29.34	21.43	38	7544	707563	49889979
Psychomotor skills impaired	28.60	21.43	11	7571	2053	50595489
Muscle rigidity	28.55	21.43	18	7564	9811	50587731
Illusion	28.39	21.43	9	7573	950	50596592
Confusional state	28.29	21.43	76	7506	185852	50411690
Extrapyramidal disorder	27.95	21.43	19	7563	11751	50585791
Drug use disorder	27.60	21.43	12	7570	3060	50594482
Newborn persistent pulmonary hypertension	27.55	21.43	6	7576	144	50597398
Abnormal behaviour	27.24	21.43	23	7559	19635	50577907
Altered state of consciousness	27.06	21.43	24	7558	21886	50575656
Myocarditis	26.77	21.43	16	7566	7931	50589611
Blood citric acid increased	26.29	21.43	5	7577	59	50597483
Dysarthria	25.98	21.43	30	7552	37373	50560169
Cardio-respiratory arrest	24.46	21.43	35	7547	53857	50543685
Schizoaffective disorder	24.43	21.43	10	7572	2196	50595346
Dyspnoea	24.14	21.43	28	7554	547580	50049962
Tremor	23.90	21.43	53	7529	114850	50482692
Mitochondrial enzyme deficiency	22.44	21.43	4	7578	32	50597510
Bradyphrenia	22.34	21.43	13	7569	6139	50591403
Maternal exposure during pregnancy	22.00	21.43	63	7519	159715	50437827
Anger	21.60	21.43	16	7566	11317	50586225

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	303.69	16.72	132	9190	16016	29549189
Catatonia	119.38	16.72	47	9275	4421	29560784
Decreased eye contact	102.61	16.72	25	9297	460	29564745
Oppositional defiant disorder	100.36	16.72	25	9297	506	29564699
Emotional poverty	98.33	16.72	24	9298	445	29564760
Psychotic disorder	94.45	16.72	66	9256	20288	29544917
Aggression	92.70	16.72	82	9240	35459	29529746
Extrapyramidal disorder	87.74	16.72	50	9272	10781	29554424
Bruxism	85.24	16.72	28	9294	1559	29563646
Psychomotor hyperactivity	83.33	16.72	44	9278	8169	29557036
Tardive dyskinesia	76.54	16.72	36	9286	5222	29559983
Homicidal ideation	76.12	16.72	29	9293	2495	29562710
Foetal disorder	68.17	16.72	20	9302	763	29564442
Sedation	66.08	16.72	50	9272	17355	29547850
Parkinsonism	65.47	16.72	36	9286	7242	29557963
Foetal exposure during pregnancy	63.26	16.72	65	9257	33802	29531403
Drug withdrawal syndrome neonatal	61.26	16.72	27	9295	3368	29561837
Neutropenia neonatal	58.16	16.72	17	9305	640	29564565
Suicide attempt	57.52	16.72	62	9260	34048	29531157
Dyskinesia	55.71	16.72	48	9274	20013	29545192
Schizophrenia	49.67	16.72	29	9293	6536	29558669
Hyperkinesia	46.88	16.72	18	9304	1581	29563624
Choreoathetosis	46.85	16.72	16	9306	1004	29564201
Crying	46.84	16.72	26	9296	5325	29559880
Delusion of grandeur	46.56	16.72	13	9309	414	29564791
Trismus	46.49	16.72	20	9302	2353	29562852
Dystonia	43.77	16.72	31	9291	9718	29555487
Sopor	40.58	16.72	31	9291	10903	29554302
Irritability	40.41	16.72	42	9280	22110	29543095
Suicidal ideation	40.08	16.72	52	9270	34664	29530541
Coordination abnormal	39.99	16.72	26	9296	7088	29558117
Hallucination, auditory	39.62	16.72	29	9293	9564	29555641
Congenital cerebrovascular anomaly	35.79	16.72	6	9316	12	29565193
Insomnia	35.40	16.72	83	9239	88678	29476527
Blood creatine phosphokinase increased	35.16	16.72	53	9269	40591	29524614
Dextrocardia	34.81	16.72	8	9314	113	29565092
Somnolence	34.40	16.72	85	9237	93870	29471335
Affect lability	33.86	16.72	18	9304	3384	29561821
Premature baby	33.76	16.72	34	9288	17246	29547959
Agitation	33.63	16.72	59	9263	51245	29513960
Foetal alcohol syndrome	33.37	16.72	8	9314	137	29565068
Intentional self-injury	32.94	16.72	29	9293	12432	29552773
Poor feeding infant	32.62	16.72	10	9312	444	29564761
Priapism	31.79	16.72	19	9303	4469	29560736
Speech disorder	31.57	16.72	38	9284	23478	29541727
Arthralgia	30.50	16.72	4	9318	139613	29425592
Sleep disorder	30.46	16.72	38	9284	24348	29540857
Salivary hypersecretion	29.70	16.72	22	9300	7387	29557818
Streptococcal infection	29.21	16.72	18	9304	4470	29560735
Mood altered	27.93	16.72	22	9300	8089	29557116
Depressed mood	27.88	16.72	30	9292	16418	29548787
Floppy iris syndrome	27.42	16.72	8	9314	299	29564906
Dyspnoea	27.33	16.72	38	9284	326694	29238511
Tachycardia	27.01	16.72	66	9256	72344	29492861
Neutrophil count increased	26.97	16.72	28	9294	14714	29550491
Affective disorder	26.84	16.72	15	9307	3111	29562094
Spasmodic dysphonia	26.50	16.72	6	9316	79	29565126
Electrocardiogram QT prolonged	25.57	16.72	43	9279	36094	29529111
Long QT syndrome	25.49	16.72	13	9309	2245	29562960
Low birth weight baby	25.10	16.72	19	9303	6589	29558616
Pneumonia aspiration	25.05	16.72	43	9279	36694	29528511
Pain in extremity	24.51	16.72	3	9319	110430	29454775
Cerebral amyloid angiopathy	24.29	16.72	6	9316	117	29565088
Overdose	23.88	16.72	67	9255	79752	29485453
Neuroblastoma	23.61	16.72	6	9316	132	29565073
Poor quality sleep	23.58	16.72	19	9303	7214	29557991
Pain	22.61	16.72	13	9309	171419	29393786
Acanthosis nigricans	22.58	16.72	6	9316	158	29565047
Drug interaction	22.57	16.72	122	9200	197263	29367942
Mental impairment	21.65	16.72	20	9302	9121	29556084
Treatment noncompliance	21.52	16.72	32	9290	24195	29541010
Portal tract inflammation	21.41	16.72	5	9317	76	29565129
Faecal vomiting	21.28	16.72	7	9315	391	29564814
Drug screen false positive	21.18	16.72	8	9314	672	29564533
Intentional overdose	21.08	16.72	41	9281	38487	29526718
Poisoning deliberate	20.72	16.72	16	9306	5715	29559490
Pulmonary valve incompetence	20.66	16.72	8	9314	719	29564486
Mania	20.60	16.72	19	9303	8644	29556561
Psychomotor retardation	19.53	16.72	12	9310	2964	29562241
Drug withdrawal syndrome	19.29	16.72	26	9296	17958	29547247
Neutropenia	18.99	16.72	87	9235	131624	29433581
Antipsychotic drug level increased	18.58	16.72	12	9310	3231	29561974
Hiccups	18.36	16.72	18	9304	8835	29556370
Toxicity to various agents	18.27	16.72	105	9217	173556	29391649
Pruritus	18.26	16.72	7	9315	116842	29448363
Delirium	18.09	16.72	39	9283	39358	29525847
Completed suicide	18.07	16.72	66	9256	90180	29475025
Sinus tachycardia	18.05	16.72	23	9299	15046	29550159
Diarrhoea	18.00	16.72	50	9272	332648	29232557
Intestinal obstruction	17.89	16.72	26	9296	19251	29545954
Echopraxia	17.58	16.72	3	9319	7	29565198
Torticollis	17.49	16.72	8	9314	1087	29564118
Depressed level of consciousness	17.46	16.72	37	9285	36905	29528300
Altered state of consciousness	17.27	16.72	26	9296	19863	29545342
Drug resistance	17.08	16.72	27	9295	21513	29543692
Therapy non-responder	17.03	16.72	33	9289	30878	29534327
Encephalopathy	16.93	16.72	33	9289	31010	29534195
Respiratory depression	16.77	16.72	21	9301	13502	29551703

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	514.52	17.03	200	14815	24796	64458921
Catatonia	245.91	17.03	85	14930	7535	64476182
Sopor	190.74	17.03	106	14909	29555	64454162
Aggression	168.54	17.03	115	14900	46117	64437600
Psychomotor hyperactivity	139.94	17.03	68	14947	14383	64469334
Suicide attempt	136.76	17.03	121	14894	70886	64412831
Tardive dyskinesia	132.42	17.03	57	14958	9121	64474596
Drug abuse	131.62	17.03	158	14857	132216	64351501
Toxicity to various agents	129.03	17.03	270	14745	363243	64120474
Psychotic disorder	125.96	17.03	86	14929	34492	64449225
Extrapyramidal disorder	120.56	17.03	68	14947	19484	64464233
Overdose	114.25	17.03	162	14853	159404	64324313
Oppositional defiant disorder	110.08	17.03	25	14990	461	64483256
Electrocardiogram QT prolonged	106.70	17.03	111	14904	79337	64404380
Decreased eye contact	103.77	17.03	26	14989	739	64482978
Intentional self-injury	98.17	17.03	69	14946	28975	64454742
Sedation	94.79	17.03	78	14937	41384	64442333
Agitation	93.58	17.03	109	14906	88258	64395459
Emotional poverty	85.82	17.03	22	14993	687	64483030
Somnolence	78.81	17.03	157	14858	203488	64280229
Coma	76.42	17.03	98	14917	87517	64396200
Hallucination, auditory	75.97	17.03	48	14967	16891	64466826
Homicidal ideation	73.84	17.03	28	14987	3229	64480488
Pneumonia aspiration	71.05	17.03	78	14937	59193	64424524
Bruxism	70.93	17.03	28	14987	3596	64480121
Intentional overdose	69.79	17.03	95	14920	89849	64393868
Mania	67.71	17.03	44	14971	16242	64467475
Salivary hypersecretion	66.31	17.03	39	14976	12074	64471643
Arthralgia	65.44	17.03	12	15003	442248	64041469
Parkinsonism	65.13	17.03	41	14974	14332	64469385
Drug interaction	61.97	17.03	205	14810	361878	64121839
Dyskinesia	61.96	17.03	60	14955	39328	64444389
Pain	61.59	17.03	26	14989	553485	63930232
Completed suicide	59.72	17.03	149	14866	224265	64259452
Blood creatine phosphokinase increased	58.26	17.03	70	14945	58488	64425229
Dystonia	55.03	17.03	41	14974	18824	64464893
Tachycardia	52.70	17.03	111	14904	149468	64334249
Dyspnoea	52.67	17.03	54	14961	718620	63765097
Choreoathetosis	50.01	17.03	17	14998	1430	64482287
Pain in extremity	49.91	17.03	6	15009	303079	64180638
Poisoning deliberate	47.86	17.03	33	14982	13425	64470292
Delusion of grandeur	46.08	17.03	13	15002	587	64483130
Altered state of consciousness	45.61	17.03	50	14965	37852	64445865
Muscle rigidity	44.43	17.03	35	14980	17438	64466279
Trismus	44.26	17.03	22	14993	4879	64478838
Hyperkinesia	44.05	17.03	18	14997	2528	64481189
Delusion	41.38	17.03	34	14981	17980	64465737
Suicidal ideation	39.55	17.03	62	14953	66480	64417237
Affect lability	39.12	17.03	25	14990	8965	64474752
Delirium	39.10	17.03	63	14952	69131	64414586
Psychomotor retardation	37.52	17.03	20	14995	5123	64478594
Mutism	37.32	17.03	15	15000	2019	64481698
Depressed level of consciousness	36.62	17.03	67	14948	81369	64402348
Priapism	36.38	17.03	18	14997	3952	64479765
Torsade de pointes	36.22	17.03	31	14984	17332	64466385
Joint swelling	36.10	17.03	4	15011	215378	64268339
Mental disorder	35.55	17.03	37	14978	26408	64457309
Respiratory depression	35.53	17.03	35	14980	23408	64460309
Irritability	35.03	17.03	43	14972	36703	64447014
Mood altered	34.30	17.03	29	14986	15950	64467767
Schizophrenia	34.20	17.03	25	14990	11143	64472574
Coordination abnormal	33.86	17.03	28	14987	14936	64468781
Stereotypy	33.50	17.03	11	15004	831	64482886
Grandiosity	33.45	17.03	10	15005	555	64483162
Confusional state	32.09	17.03	133	14882	261011	64222706
Congenital cerebrovascular anomaly	31.34	17.03	5	15010	10	64483707
Abnormal behaviour	29.90	17.03	38	14977	33584	64450133
Seizure	29.80	17.03	96	14919	166796	64316921
Intentional product misuse	29.42	17.03	57	14958	72238	64411479
Floppy iris syndrome	28.89	17.03	8	15007	337	64483380
Crying	28.61	17.03	29	14986	20061	64463656
Speech disorder	28.59	17.03	45	14970	48396	64435321
Lactate pyruvate ratio increased	28.31	17.03	6	15009	79	64483638
Treatment noncompliance	27.92	17.03	42	14973	43440	64440277
Epileptic encephalopathy	27.53	17.03	8	15007	402	64483315
Encephalopathy	27.21	17.03	49	14966	58770	64424947
Blood folate decreased	27.21	17.03	10	15005	1057	64482660
Cardiac arrest	26.94	17.03	88	14927	153976	64329741
Myocarditis	26.86	17.03	26	14989	17017	64466700
Hepatocellular injury	26.67	17.03	42	14973	45193	64438524
Neutrophil count increased	26.52	17.03	31	14984	25143	64458574
Bradyphrenia	26.44	17.03	20	14995	9386	64474331
Peripheral swelling	26.30	17.03	8	15007	209145	64274572
Disorganised speech	26.29	17.03	11	15004	1639	64482078
Streptococcal infection	25.80	17.03	18	14997	7461	64476256
Hypersensitivity	25.65	17.03	7	15008	196445	64287272
Eosinophilic myocarditis	25.54	17.03	9	15006	843	64482874
Diarrhoea	25.44	17.03	85	14930	722619	63761098
Infusion related reaction	25.29	17.03	4	15011	164463	64319254
Drug-induced liver injury	25.05	17.03	42	14973	47601	64436116
Cardio-respiratory arrest	24.72	17.03	64	14951	98329	64385388
Hyperprolactinaemia	24.67	17.03	14	15001	4051	64479666
Pruritus	24.51	17.03	22	14993	312378	64171339
Miosis	24.30	17.03	22	14993	13244	64470473
Acanthosis nigricans	24.28	17.03	6	15009	161	64483556
Antipsychotic drug level increased	24.20	17.03	15	15000	5100	64478617
Anticholinergic syndrome	24.16	17.03	12	15003	2657	64481060
Long QT syndrome	24.13	17.03	15	15000	5124	64478593
Blood citric acid increased	24.10	17.03	5	15010	59	64483658
Myalgia	24.07	17.03	4	15011	158613	64325104
Drug intolerance	23.98	17.03	7	15008	187985	64295732
Spasmodic dysphonia	23.86	17.03	6	15009	173	64483544
Fatigue	23.74	17.03	92	14923	748638	63735079
Behaviour disorder	23.46	17.03	14	15001	4448	64479269
Myoclonus	23.30	17.03	29	14986	25089	64458628
Headache	23.23	17.03	56	14959	529411	63954306
Back pain	22.95	17.03	15	15000	250156	64233561
Abdominal discomfort	22.87	17.03	7	15008	182315	64301402
Swelling	22.29	17.03	5	15010	160213	64323504
Abortion	22.28	17.03	9	15006	1227	64482490
Restlessness	22.16	17.03	36	14979	39749	64443968
Dysarthria	21.96	17.03	45	14970	59361	64424356
Hallucinations, mixed	21.89	17.03	15	15000	6037	64477680
Parkinsonian gait	21.81	17.03	8	15007	841	64482876
Poisoning	21.49	17.03	26	14989	21853	64461864
Tremor	21.01	17.03	79	14936	148151	64335566
Akathisia	20.91	17.03	19	14996	11491	64472226
Affective disorder	20.76	17.03	15	15000	6565	64477152
Portal tract inflammation	20.53	17.03	5	15010	126	64483591
Drug screen false positive	20.44	17.03	8	15007	1004	64482713
Cerebral amyloid angiopathy	20.35	17.03	6	15009	317	64483400
Hepatic enzyme increased	20.34	17.03	3	15012	129940	64353777
Torticollis	20.33	17.03	10	15005	2167	64481550
Illusion	20.20	17.03	9	15006	1561	64482156
Schizoaffective disorder	20.11	17.03	9	15006	1578	64482139
Depressed mood	20.04	17.03	35	14980	40977	64442740
Drug resistance	19.87	17.03	32	14983	35070	64448647
Nausea	19.85	17.03	105	14910	785695	63698022
Rash	19.71	17.03	49	14966	458500	64025217
Echolalia	19.60	17.03	6	15009	361	64483356
Drug use disorder	19.56	17.03	14	15001	6040	64477677
Neuroblastoma	19.27	17.03	5	15010	164	64483553
Cough	18.53	17.03	26	14989	302122	64181595
Withdrawal syndrome	18.48	17.03	25	14990	23467	64460250
Mixed anxiety and depressive disorder	18.46	17.03	5	15010	194	64483523
Sleep disorder	18.37	17.03	42	14973	59667	64424050
Cogwheel rigidity	17.79	17.03	10	15005	2843	64480874
Sinus tachycardia	17.75	17.03	29	14986	32159	64451558
White blood cell count increased	17.68	17.03	44	14971	65970	64417747
Psychomotor skills impaired	17.49	17.03	11	15004	3834	64479883
Pneumoconiosis	17.37	17.03	5	15010	243	64483474
Hyperammonaemia	17.31	17.03	16	14999	9888	64473829
Neutropenia	17.28	17.03	105	14910	239519	64244198
Physical assault	17.17	17.03	8	15007	1538	64482179

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AA01	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with aliphatic side-chain
FDA CS	M0016525	Phenothiazines
CHEBI has role	CHEBI:37930	phenothiazine antipsychotic drugs
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:149553	anticoronaviral drug
MeSH PA	D000932	Antiemetics
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
FDA EPC	N0000175746	Phenothiazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Disruptive behavior disorder	indication	54319003
Schizophrenia	indication	58214004	DOID:5419
Psychotic disorder	indication	69322001
Bipolar affective disorder, current episode manic	indication	191618007
Acute intermittent porphyria	indication	234422006	DOID:3890
Pre-Op Apprehension	indication
Tetanus Adjunct Treatment	indication
Intractable Hiccups	indication
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Acute disease of cardiovascular system	contraindication	128487001
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.04	Basic
pKa2	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG/ML	CHLORPROMAZINE HYDROCHLORIDE	GENUS	A214542	June 2, 2021	RX	CONCENTRATE	ORAL	Jan. 29, 2022	COMPETITIVE GENERIC THERAPY
30MG/ML	CHLORPROMAZINE HYDROCHLORIDE	GENUS	A214542	June 2, 2021	RX	CONCENTRATE	ORAL	Jan. 29, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.15	WOMBAT-PK	CHEMBL
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	5.23	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.19	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.20	WOMBAT-PK
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.72	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.83	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	6.22	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	6.92	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	7.72	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.17	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	8.10	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.28	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.40	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.44	WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	7.41	WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	9.55	PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.60	WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.54	WOMBAT-PK
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	6.93	WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.20	WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	6.76	PDSP
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	6.87	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.60	PDSP
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.75	PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.25	PDSP
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.40	PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.38	PDSP
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.24	WOMBAT-PK
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	5.83	PDSP
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	6.35	PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.10	WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.68	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.16	WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	ANTAGONIST	Ki	7.69	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	8.71	DRUG MATRIX
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	6.01	PDSP
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	9.09	PDSP
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.35	DRUG MATRIX
Calmodulin	Cytosolic other	P0DP23 P0DP24 P0DP25	CALM1_HUMAN CALM2_HUMAN CALM3_HUMAN		Kd	5.91	CHEMBL
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.13	DRUG MATRIX
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.93	PDSP
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		Ki	6.46	PDSP
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	4.54	DRUG MATRIX
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN		IC50	5.57	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.06	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	4.71	DRUG MATRIX
Ryanodine receptor 1	Ion channel	P21817	RYR1_HUMAN		IC50	3.57	WOMBAT-PK
Major prion protein	Surface antigen	P04156	PRIO_HUMAN		EC50	5.70	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.57	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.04	DRUG MATRIX
Melanocortin receptor 4	GPCR	P32245	MC4R_HUMAN		Ki	4.84	DRUG MATRIX
Melanocortin receptor 5	GPCR	P33032	MC5R_HUMAN		Ki	5.15	DRUG MATRIX
Melanocortin receptor 3	GPCR	P41968	MC3R_HUMAN		Ki	4.67	DRUG MATRIX
Glutamate [NMDA] receptor	Ion channel	O15399 O60391 Q05586 Q12879 Q13224 Q14957 Q8TCU5	NMDE4_HUMAN NMD3B_HUMAN NMDZ1_HUMAN NMDE1_HUMAN NMDE2_HUMAN NMDE3_HUMAN NMD3A_HUMAN		IC50	6.22	CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.37	CHEMBL
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	5.99	CHEMBL
Sphingomyelin phosphodiesterase	Enzyme	P17405	ASM_HUMAN		IC50	4.96	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.85	WOMBAT-PK
Trypanothione reductase	Enzyme		TYTR_TRYCR		Ki	5.49	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	4.80	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	8.31	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.74	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.78	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	8.07	CHEMBL
Histamine H1 receptor	GPCR		HRH1_CAVPO		Ki	7.30	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.92	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	6.75	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	7.68	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_MOUSE	ANTAGONIST	Ki	5.30	IUPHAR
D(1A) dopamine receptor	GPCR		DRD1_RAT		Ki	7.46	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		IC50	7.10	CHEMBL
Transient receptor potential cation channel subfamily V member 1	Ion channel		TRPV1_RAT		Ki	5.89	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	8.40	IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.35	CHEMBL
Acetylcholine receptor subunit alpha	Ion channel		ACHA_TORCA		IC50	5.89	CHEMBL
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT		IC50	5.89	CHEMBL
Muscarinic acetylcholine receptor	GPCR		ACM1_RAT ACM3_RAT ACM4_RAT ACM5_RAT ACM2_RAT		Ki	7.22	CHEMBL
Dopamine receptor	GPCR		DRD2_BOVIN DRD1_BOVIN		IC50	7.60	CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD3_RAT DRD5_RAT DRD4_RAT DRD2_RAT		Ki	7.85	CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	9.15	CHEMBL
Adenylate cyclase	Enzyme		D4A3N4_RAT ADCY3_RAT ADCY2_RAT ADCY4_RAT ADCY8_RAT ADCY6_RAT ADCY5_RAT Q8CFM9_RAT		Ki	6.93	CHEMBL
Calmodulin	Cytosolic other		CALM_BOVIN		IC50	5.60	CHEMBL
Major prion protein	Unclassified		PRIO_MOUSE		EC50	5.70	CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	Enzyme		AT2A1_RABIT		IC50	4.64	CHEMBL

External reference:

ID	Source
4017861	VUID
N0000146214	NUI
D00270	KEGG_DRUG
69-09-0	SECONDARY_CAS_RN
104728	RXNORM
4017860	VANDF
4017861	VANDF
C0008286	UMLSCUI
CHEBI:3647	CHEBI
CHEMBL71	ChEMBL_ID
CHEMBL1713	ChEMBL_ID
DB00477	DRUGBANK_ID
D002746	MESH_DESCRIPTOR_UI
2726	PUBCHEM_CID
83	IUPHAR_LIGAND_ID
183	INN_ID
U42B7VYA4P	UNII
2140	MMSL
4264	MMSL
4428	MMSL
4429	MMSL
71853	MMSL
d00064	MMSL
001470	NDDF
004587	NDDF
387258005	SNOMEDCT_US
387479008	SNOMEDCT_US
47331002	SNOMEDCT_US
Z80	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CHLORPROMAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9836	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2961	TABLET, COATED	10 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2962	TABLET, COATED	25 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2963	TABLET, COATED	50 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2964	TABLET, COATED	100 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2965	TABLET, COATED	200 mg	ORAL	ANDA	14 sections
Chlorpromazine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-1397	INJECTION	25 mg	INTRAMUSCULAR	ANDA	17 sections
Chlorpromazine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-1398	INJECTION	25 mg	INTRAMUSCULAR	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5913	TABLET, SUGAR COATED	10 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5914	TABLET, SUGAR COATED	25 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5915	TABLET, SUGAR COATED	50 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5916	TABLET, SUGAR COATED	100 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5917	TABLET, SUGAR COATED	200 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0300	TABLET, SUGAR COATED	10 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0301	TABLET, SUGAR COATED	25 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0302	TABLET, SUGAR COATED	50 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0303	TABLET, SUGAR COATED	100 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0304	TABLET, SUGAR COATED	200 mg	ORAL	ANDA	14 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6017	TABLET, FILM COATED	10 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6018	TABLET, FILM COATED	25 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6019	TABLET, FILM COATED	50 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6020	TABLET, FILM COATED	100 mg	ORAL	ANDA	17 sections
Chlorpromazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6021	TABLET, FILM COATED	200 mg	ORAL	ANDA	17 sections
CHLORPROMAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6892	TABLET, FILM COATED	10 mg	ORAL	ANDA	13 sections
CHLORPROMAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6893	TABLET, FILM COATED	25 mg	ORAL	ANDA	13 sections
CHLORPROMAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6894	TABLET, FILM COATED	50 mg	ORAL	ANDA	13 sections
CHLORPROMAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6895	TABLET, FILM COATED	100 mg	ORAL	ANDA	13 sections
CHLORPROMAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6896	TABLET, FILM COATED	200 mg	ORAL	ANDA	13 sections
Chlorpromazine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7129	TABLET, FILM COATED	10 mg	ORAL	ANDA	13 sections
Chlorpromazine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7130	TABLET, FILM COATED	25 mg	ORAL	ANDA	13 sections